2 ︳PATIENTS AND METHODS
Patients with pre-BLL included in this study were diagnosed and treated
in the Shanghai Children’s Medical Center (SCMC) from January 2001 to
December 2020. The diagnosis was determined by cell morphology,
flow-cytometric and molecular biologic analysis. The diagnostic criteria
were based of French–American–British (FAB) classification and
European Group for the Immunological Characterization of Leukemias
criteria5, 6. The presence of c-MYC arrangement was
confirmed by fluorescence in situ hybridization (FISH). Patient data
analyses included basic clinical information: gender, age and
extramedullary infiltration; laboratory information: white blood cell
count, serum UA, LDH level; and details of treatments and outcomes. This
study was approved by the institutional review board of the SCMC.